Correction : Barclays Maintains Overweight on Avidity Biosciences, Raises Price Target to $59 (Firm Changed)

Benzinga · 2d ago

Correction :Barclays analyst Gena Wang maintains Avidity Biosciences (NASDAQ:RNA) with a Overweight and raises the price target from $57 to $59. (Firm Changed)